The global Radionuclide Drug Conjugates (RDC) market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of % from 2025 to 2031.

RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.

According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.

At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.

According to different targeting ligands, RDC can be subdivided into: antibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).

According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.

ReportPrime' newest research report, the “Radionuclide Drug Conjugates (RDC) Industry Forecast” looks at past sales and reviews total world Radionuclide Drug Conjugates (RDC) sales in 2024, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugates (RDC) sales for 2025 through 2031. With Radionuclide Drug Conjugates (RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radionuclide Drug Conjugates (RDC) industry.

This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugates (RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugates (RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radionuclide Drug Conjugates (RDC) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugates (RDC) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugates (RDC).

This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugates (RDC) market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Antibody Radionuclide Conjugates (ARC)
• Peptide Radionuclide Conjugates (PRC)
• Small Molecular Radionuclide Conjugates (SMRC)

Segmentation by Application:

• Neuroendocrine Tumors
• Prostate Cancer
• Renal Cell Carcinoma

Market by Region:

• Americas
1. United States
2. Canada
3. Mexico
4. Brazil

• APAC
1. China
2. Japan
3. Korea
4. Southeast Asia
5. India
6. Australia

• Europe
1. Germany
2. France
3. UK
4. Italy
5. Russia

• Middle East & Africa
1. Egypt
2. South Africa
3. Israel
4. Turkey
5. GCC Countries

Company's Coverage:

• POINT Biopharma
• Telix
• ITM AG
• Bayer AG
• Novartis
• Lantheus
• Curium Pharma
• Uihc Pet Imaging
• Grand Pharma
• BoomRay Pharmaceuticals
• SmartNuclide Biopharma
• Hengrui Medicine
• Yunnan Baiyao Group
• Sinotau
• Hexin Pharmaceutical
• Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

Key Questions Addressed in this Report:

Not provided in the input.